Alvotech Lines Up US Biosimilar Approvals After FDA Inspection

AVT02 Adalimumab And AVT04 Ustekinumab Approvals Expected Early This Year

 
• By David Wallace
  
Calendar showing February to April 2024
Alvotech said it expects approvals in early 2024 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products